MX2018009413A - Composiciones que contienen tucaresol o sus analogos. - Google Patents
Composiciones que contienen tucaresol o sus analogos.Info
- Publication number
- MX2018009413A MX2018009413A MX2018009413A MX2018009413A MX2018009413A MX 2018009413 A MX2018009413 A MX 2018009413A MX 2018009413 A MX2018009413 A MX 2018009413A MX 2018009413 A MX2018009413 A MX 2018009413A MX 2018009413 A MX2018009413 A MX 2018009413A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- formula
- tucaresol
- analogs
- compositions containing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 title 1
- 229950009795 tucaresol Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 230000006044 T cell activation Effects 0.000 abstract 1
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 abstract 1
- 229950011498 plinabulin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describen en la presente composiciones que incluyen un compuesto de la formula (I) para tratar cáncer. Algunas modalidades se refieren a métodos para tratar cáncer por co-administración de un compuesto de la formula (I) y un inhibidores de puntos de control inmunitarios a un sujeto en necesidad de los mismos. Algunas modalidades se refieren a métodos para tratar cáncer por co-administración de un compuesto de la fórmula (I) y plinabulina a un sujeto en necesidad de los mismos. Algunas modalidades se refieren a la provisión de co-estimulación de activación de células T contra cáncer por co-administración de un compuesto de la formula (I), uno o más inhibidores de puntos de control inmunitarios.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662292763P | 2016-02-08 | 2016-02-08 | |
PCT/US2017/016740 WO2017139231A1 (en) | 2016-02-08 | 2017-02-06 | Compositions containing tucaresol or its analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018009413A true MX2018009413A (es) | 2019-05-15 |
Family
ID=59563990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009413A MX2018009413A (es) | 2016-02-08 | 2017-02-06 | Composiciones que contienen tucaresol o sus analogos. |
Country Status (18)
Country | Link |
---|---|
US (2) | US10912748B2 (es) |
EP (1) | EP3413885A4 (es) |
JP (2) | JP2019511565A (es) |
KR (1) | KR20180105685A (es) |
CN (1) | CN108778267A (es) |
AU (1) | AU2017217426B2 (es) |
BR (1) | BR112018016054A2 (es) |
CA (1) | CA3013467A1 (es) |
CO (1) | CO2018009096A2 (es) |
EC (1) | ECSP18067631A (es) |
IL (1) | IL260933B2 (es) |
MX (1) | MX2018009413A (es) |
MY (1) | MY192703A (es) |
NZ (1) | NZ744854A (es) |
PH (1) | PH12018501669A1 (es) |
RU (1) | RU2753543C1 (es) |
SG (1) | SG11201806583XA (es) |
WO (1) | WO2017139231A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6904570B2 (ja) | 2015-03-06 | 2021-07-21 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | 脳腫瘍の治療方法 |
CN107530341B (zh) | 2015-03-06 | 2021-10-01 | 大连万春布林医药有限公司 | 治疗与ras突变相关的癌症的方法 |
BR112018000229A2 (pt) | 2015-07-13 | 2018-09-04 | Beyondspring Pharmaceuticals Inc | composições de plinabulina |
SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
AU2017278245B2 (en) | 2016-06-06 | 2022-09-15 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing neutropenia |
CN110431135A (zh) | 2017-01-06 | 2019-11-08 | 大连万春布林医药有限公司 | 微管蛋白结合化合物及其治疗用途 |
KR20190109479A (ko) | 2017-02-01 | 2019-09-25 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
DK3595653T3 (da) * | 2017-03-13 | 2023-04-17 | Beyondspring Pharmaceuticals Inc | Sammensætninger af plinabulin og anvendelse heraf |
CN109420167B (zh) * | 2017-08-28 | 2022-02-11 | 四川九章生物科技有限公司 | 一种治疗肿瘤的联合用药物 |
JP7350015B2 (ja) | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
US20220395584A1 (en) * | 2019-03-14 | 2022-12-15 | Engene, Inc | Reversible coating of chitosan-nucleic acid nanoparticles and methods of their use |
AU2020343329A1 (en) * | 2019-09-03 | 2022-03-24 | Intra-Cellular Therapies, Inc. | Methods of treatment |
CN112778155B (zh) * | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | 妥卡雷琐衍生物及其用途 |
JP2023524530A (ja) * | 2020-05-04 | 2023-06-12 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | 免疫原性が低い癌の癌細胞死滅を増強するための3剤併用療法 |
Family Cites Families (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2053218B (en) * | 1979-06-29 | 1984-01-25 | Wellcome Found | Pharmaceutical ethers of 2,6-dihydroxybenzaldehyde |
IL64573A (en) | 1980-12-18 | 1985-04-30 | Wellcome Found | Derivatives of formylphenoxyalkanoic acids and formylphenoxymethylbenzoic acids,their preparation and pharmaceutical formulations containing them |
AU576322B2 (en) | 1983-07-22 | 1988-08-25 | Ici Australia Limited | Alpha-substituted-alpha-cyanomethyl alcohols |
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
JPH05255106A (ja) | 1990-10-31 | 1993-10-05 | Toray Ind Inc | 血小板減少症治療剤 |
JPH059164A (ja) | 1991-07-02 | 1993-01-19 | Sumitomo Chem Co Ltd | 光学活性マンデロニトリル誘導体の製造方法 |
GB9217331D0 (en) | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
DE69306545T2 (de) * | 1992-10-01 | 1997-04-03 | Wellcome Found | Tucaresol als Mittel zur Immunopotentierung |
US5872151A (en) | 1992-10-01 | 1999-02-16 | Glaxo Wellcome Inc. | Immunopotentiatory agents and physiologically acceptable salts thereof |
US6096786A (en) * | 1992-10-01 | 2000-08-01 | Glaxo Wellcome Inc. | Immunopotentiatory agent and physiologically acceptable salts thereof |
ES2224200T3 (es) | 1992-11-27 | 2005-03-01 | Mayne Pharma (Usa) Inc. | Composicion inyectable estable de paclitaxel. |
JPH0725858A (ja) | 1993-07-13 | 1995-01-27 | Otsuka Pharmaceut Co Ltd | ピペラジン誘導体 |
US5958980A (en) * | 1993-08-26 | 1999-09-28 | Glaxo Wellcome, Inc. | Immunopotentiatory agent and physiologically acceptable salts thereof |
IL110787A0 (en) | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
GB9402807D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
GB9402809D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
GB9426224D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
US5891877A (en) | 1995-02-14 | 1999-04-06 | Xenova Limited | Pharmaceutical compounds |
US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
JP3131574B2 (ja) | 1996-09-04 | 2001-02-05 | 新日本製鐵株式会社 | 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤 |
US5939098A (en) | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
WO1999026614A1 (en) | 1997-11-21 | 1999-06-03 | Euro-Celtique S.A. | Substituted 2-aminoacetamides and the use thereof |
HUP0101329A3 (en) | 1998-01-29 | 2002-07-29 | Aventis Pharmaceuticals Inc Co | Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compounds and a cyclyzed compounds there from |
US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
US6069146A (en) | 1998-03-25 | 2000-05-30 | The Regents Of The University Of California | Halimide, a cytotoxic marine natural product, and derivatives thereof |
NZ506435A (en) | 1998-03-26 | 2002-08-28 | Shionogi & Co | 3-Indoly-2-hydroxy-4-oxo-2-butanoic acid useful as antiviral activity |
US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
GB9818627D0 (en) | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6358957B1 (en) | 1998-11-12 | 2002-03-19 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
US7026322B2 (en) | 1998-11-12 | 2006-04-11 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
DE60033293D1 (de) | 1999-08-23 | 2007-03-22 | Dana Farber Cancer Inst Inc | Neue b7-4 moleküle und deren verwendungen |
CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
IL150430A0 (en) | 2000-01-18 | 2002-12-01 | Nereus Pharmaceuticals Inc | Cell division inhibitors and process for producing the same |
WO2001070663A2 (en) * | 2000-03-17 | 2001-09-27 | Corixa Corporation | Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
CZ301743B6 (cs) | 2000-05-09 | 2010-06-09 | Angiorx Corporation | Piperazindionové slouceniny a protinádorové využití |
US6583143B2 (en) | 2000-12-28 | 2003-06-24 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
US20030082140A1 (en) | 2001-08-20 | 2003-05-01 | Fisher Paul B. | Combinatorial methods for inducing cancer cell death |
WO2003074550A2 (en) | 2002-03-01 | 2003-09-12 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
WO2003097164A1 (en) | 2002-05-17 | 2003-11-27 | Aventis Pharma S.A. | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
CN100540548C (zh) | 2002-08-02 | 2009-09-16 | 尼瑞斯药品公司 | 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成 |
US7935704B2 (en) | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
SE0202429D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
EP1711487A1 (en) | 2004-02-04 | 2006-10-18 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
US7999106B2 (en) | 2004-04-19 | 2011-08-16 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form I |
ES2427646T5 (es) | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
MX2007015942A (es) | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
EP1926724A1 (en) | 2005-09-21 | 2008-06-04 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
US20090130098A1 (en) | 2006-01-18 | 2009-05-21 | Merck Patent Gmbh | Specific therapy using integrin ligands for treating cancer |
EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
MX2009008620A (es) * | 2007-02-15 | 2009-10-22 | Mannkind Corp | Un metodo para mejorar la respuesta de celulas t. |
WO2008128169A1 (en) | 2007-04-13 | 2008-10-23 | Abraxis Bioscience, Inc. | Sparc and methods of use thereof |
US20090170837A1 (en) | 2007-08-17 | 2009-07-02 | Thallion Pharmaceuticals Inc. | Methods for treating ras driven cancer in a subject |
US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
EP2962731A1 (en) | 2008-01-08 | 2016-01-06 | Bristol-Myers Squibb Company | Combination of ipilimumab and paclitaxel for the treatment of cancer |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
HUE034832T2 (hu) | 2008-12-09 | 2021-12-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására |
UA103221C2 (uk) | 2009-01-16 | 2013-09-25 | Тева Фармасьютікал Індастріз Лтд. | Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини |
WO2010114922A1 (en) | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
ES2543280T3 (es) | 2009-08-10 | 2015-08-17 | Board Of Regents, The University Of Texas System | Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico |
CA2774015A1 (en) | 2009-09-15 | 2011-03-24 | Cerulean Pharma Inc. | A cdp-camptothecin conjugate, particle or composition and uses thereof |
WO2011050344A2 (en) * | 2009-10-23 | 2011-04-28 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
CN101766815B (zh) | 2009-12-31 | 2012-04-25 | 胡松华 | 紫杉醇及多西紫杉醇的用途 |
EP2542699A4 (en) | 2010-03-03 | 2013-10-02 | Targeted Molecular Diagnostics Llc | METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION |
US20130064831A1 (en) | 2010-05-17 | 2013-03-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
CA2799653A1 (en) | 2010-06-04 | 2011-12-08 | Bertrand Leblond | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
JP2012033526A (ja) | 2010-07-28 | 2012-02-16 | Fuji Electric Co Ltd | 薄膜太陽電池およびその製造方法 |
WO2012035436A1 (en) * | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
US20120214679A1 (en) | 2010-11-29 | 2012-08-23 | Precision Therapeutics, Inc. | Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents |
TWI386203B (zh) | 2011-01-07 | 2013-02-21 | Univ China Medical | 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用 |
MX338353B (es) | 2011-04-20 | 2016-04-13 | Medimmune Llc | Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. |
US20140349878A1 (en) | 2011-11-28 | 2014-11-27 | National Research Council Of Canada | Paclitaxel response markers for cancer |
WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
PT2846809T (pt) | 2012-05-09 | 2021-02-05 | Cantex Pharmaceuticals Inc | Tratamento de mielossupressão |
AU2013204313C1 (en) | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
CA2889182A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
RU2708032C2 (ru) | 2013-02-20 | 2019-12-03 | Новартис Аг | ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII |
EP2968536B1 (en) | 2013-03-13 | 2023-06-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for modulating chemotherapeutic cytotoxicity |
US10809323B2 (en) | 2013-04-24 | 2020-10-20 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Magnetic resonance maps for analyzing tissue |
KR20160013049A (ko) | 2013-06-03 | 2016-02-03 | 노파르티스 아게 | 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물 |
WO2015051543A1 (en) | 2013-10-11 | 2015-04-16 | Dalian Wanchun Biotechnology Co., Ltd. | Cancer treatment with combination of plinabulin and taxane |
IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and cancer drugs |
ES2738289T3 (es) | 2013-11-06 | 2020-01-21 | Hospital Clinic Barcelona | Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión |
CN104796448B (zh) | 2014-01-22 | 2019-02-12 | 腾讯科技(深圳)有限公司 | 网络系统的数据处理方法和装置 |
US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
CN106794246B (zh) * | 2014-08-08 | 2021-10-15 | OncoQuest制药有限公司 | 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能 |
WO2016081281A1 (en) | 2014-11-17 | 2016-05-26 | Salk Institute For Biological Studies | Lipophilic bisphosphonates and methods of use |
EP3256130A4 (en) | 2015-02-12 | 2018-08-01 | Beyondspring Pharmaceuticals, Inc. | Use of plinabulin in combination with immune checkpoint inhibitors |
CN107530341B (zh) | 2015-03-06 | 2021-10-01 | 大连万春布林医药有限公司 | 治疗与ras突变相关的癌症的方法 |
JP6904570B2 (ja) | 2015-03-06 | 2021-07-21 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | 脳腫瘍の治療方法 |
WO2016165007A1 (en) | 2015-04-17 | 2016-10-20 | The University Of British Columbia | Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer |
CN106279039B (zh) | 2015-06-02 | 2019-01-11 | 青岛海洋生物医药研究院股份有限公司 | 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用 |
BR112018000229A2 (pt) | 2015-07-13 | 2018-09-04 | Beyondspring Pharmaceuticals Inc | composições de plinabulina |
EP3359692A4 (en) | 2015-10-05 | 2019-05-01 | Cedars-Sinai Medical Center | METHOD OF CLASSIFYING AND DIAGNOSING CANCER |
SG11201806583XA (en) * | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
AU2017278245B2 (en) | 2016-06-06 | 2022-09-15 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing neutropenia |
CN110431135A (zh) | 2017-01-06 | 2019-11-08 | 大连万春布林医药有限公司 | 微管蛋白结合化合物及其治疗用途 |
KR20190109479A (ko) | 2017-02-01 | 2019-09-25 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
DK3595653T3 (da) | 2017-03-13 | 2023-04-17 | Beyondspring Pharmaceuticals Inc | Sammensætninger af plinabulin og anvendelse heraf |
US10933061B2 (en) | 2017-12-21 | 2021-03-02 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate therapies and methods of use |
JP7350015B2 (ja) | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
SG11202006990TA (en) | 2018-02-01 | 2020-08-28 | Beyondspring Pharmaceuticals Inc | Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent |
CN110240592A (zh) | 2018-03-08 | 2019-09-17 | 青岛海洋生物医药研究院股份有限公司 | (z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用 |
CN111936143A (zh) | 2018-04-05 | 2020-11-13 | 诺维嘉研究公司 | 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品 |
US20210161888A1 (en) | 2018-06-01 | 2021-06-03 | Beyondspring Pharmaceuticals, Inc. | Composition and method of treating cancer associated with egfr mutation |
CN112638388A (zh) | 2018-08-16 | 2021-04-09 | 大连万春布林医药有限公司 | 刺激免疫反应的方法和组合物 |
US20230035763A1 (en) | 2018-11-14 | 2023-02-02 | BeyondSpring Pharnaceuticals, Inc. | Methods of treating cancer using tubulin binding agents |
CN112778155B (zh) | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | 妥卡雷琐衍生物及其用途 |
JP2023524530A (ja) | 2020-05-04 | 2023-06-12 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | 免疫原性が低い癌の癌細胞死滅を増強するための3剤併用療法 |
-
2017
- 2017-02-06 SG SG11201806583XA patent/SG11201806583XA/en unknown
- 2017-02-06 CA CA3013467A patent/CA3013467A1/en active Pending
- 2017-02-06 CN CN201780018762.6A patent/CN108778267A/zh active Pending
- 2017-02-06 US US16/075,942 patent/US10912748B2/en active Active
- 2017-02-06 MX MX2018009413A patent/MX2018009413A/es unknown
- 2017-02-06 EP EP17750611.0A patent/EP3413885A4/en active Pending
- 2017-02-06 IL IL260933A patent/IL260933B2/en unknown
- 2017-02-06 JP JP2018560724A patent/JP2019511565A/ja active Pending
- 2017-02-06 AU AU2017217426A patent/AU2017217426B2/en active Active
- 2017-02-06 BR BR112018016054-7A patent/BR112018016054A2/pt not_active Application Discontinuation
- 2017-02-06 NZ NZ744854A patent/NZ744854A/en unknown
- 2017-02-06 RU RU2018128290A patent/RU2753543C1/ru active
- 2017-02-06 KR KR1020187024294A patent/KR20180105685A/ko active Search and Examination
- 2017-02-06 WO PCT/US2017/016740 patent/WO2017139231A1/en active Application Filing
- 2017-02-06 MY MYPI2018702720A patent/MY192703A/en unknown
-
2018
- 2018-08-06 PH PH12018501669A patent/PH12018501669A1/en unknown
- 2018-08-29 CO CONC2018/0009096A patent/CO2018009096A2/es unknown
- 2018-09-07 EC ECSENADI201867631A patent/ECSP18067631A/es unknown
-
2021
- 2021-02-08 US US17/170,058 patent/US11857522B2/en active Active
-
2022
- 2022-04-07 JP JP2022063979A patent/JP2022088662A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190380983A1 (en) | 2019-12-19 |
KR20180105685A (ko) | 2018-09-28 |
SG11201806583XA (en) | 2018-09-27 |
EP3413885A4 (en) | 2019-09-18 |
EP3413885A1 (en) | 2018-12-19 |
CN108778267A (zh) | 2018-11-09 |
PH12018501669A1 (en) | 2019-06-17 |
US11857522B2 (en) | 2024-01-02 |
US10912748B2 (en) | 2021-02-09 |
WO2017139231A1 (en) | 2017-08-17 |
ECSP18067631A (es) | 2018-09-30 |
NZ744854A (en) | 2020-01-31 |
RU2753543C1 (ru) | 2021-08-17 |
JP2019511565A (ja) | 2019-04-25 |
JP2022088662A (ja) | 2022-06-14 |
US20210161844A1 (en) | 2021-06-03 |
IL260933B (en) | 2022-12-01 |
MY192703A (en) | 2022-09-02 |
AU2017217426A1 (en) | 2018-08-23 |
BR112018016054A2 (pt) | 2019-02-12 |
CO2018009096A2 (es) | 2019-04-30 |
AU2017217426B2 (en) | 2022-12-01 |
CA3013467A1 (en) | 2017-08-17 |
IL260933A (en) | 2018-10-31 |
IL260933B2 (en) | 2023-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501669A1 (en) | Compositions containing tucaresol or its analogs | |
MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
MX2019011431A (es) | Inhibidores de proteina 1 de muerte celular programada (pd-1)/ligando 1 de muerte programada (pd-l1). | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
PH12017501413A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
NZ742742A (en) | Compositions and methods for inhibiting arginase activity | |
CL2016003350A1 (es) | Inhibidores de demetilasa-1 especifica de lisina | |
CL2019000844A1 (es) | Compuesto de piridina. | |
MX2018002049A (es) | Diacereina o sus analogos para inhibir la expresion de proteina como mota relacionada a la apoptosis que contiene un dominio de reclutamiento de caspasa (asc), expresion de dominios de pirina y familia nlr que contienen 3 (nlrp3) y/o formacion de complejo de inflamasoma de nlrp3. | |
PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
MX2016011897A (es) | Composiciones de compuestos selenoorganicos y metodos de uso de los mismos. | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
DOP2017000111A (es) | Inhibidor de cinasa aurora a | |
PH12016502130A1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
PH12017501879A1 (en) | Methods for treating cancer | |
MX2017012068A (es) | Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos. | |
MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
SV2019005838A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
NZ757526A (en) | Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction | |
MX2020005454A (es) | Tratamiento de cancer mejorado. | |
IN2013DE03665A (es) | ||
CR20150593A (es) | Potenciador de inhibidores del homólogo de zeste |